Vicore completes ASPIRE enrollment, adds US listing and new CSO in Q2 2026
Vicore Pharma finished patient recruitment for its Phase 2b IPF trial ahead of schedule and began trading its ADSs on Nasdaq Capital Market in July.
SEC filing
Latest
1 story
Sign in